Search - tctmd.com

Displaying 121 - 140 of 364

Sort: Relevancy | Date

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

Caitlin E. Cox

February 17, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

News Daily News

After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD

Michael O'Riordan

December 14, 2016

News Industry News

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

November 29, 2016

News Conference News TCT 2016

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

Yael L. Maxwell

November 08, 2016

News Industry News

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

November 03, 2016

News Industry News TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

November 02, 2016

Presentation TCT 2016

PRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients With Coronary Artery Chronic Total Occlusions

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Koen Teeuwen

November 02, 2016

Presentation TCT 2016

NeoVas PLLA-Based Sirolimus-Eluting Scaffold: Early Results and Phase III Completion

Presenter: Ron Waksman, Robert-Jan van Geuns, Guosheng Fu

October 31, 2016

Presentation TCT 2016

FIRESORB PLLA-Based Sirolimus-Eluting Scaffold: 6-Month FUTURE-I Results

Presenter: Ron Waksman, Robert-Jan van Geuns, Bo Xu

October 31, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

TCT 261: Impact of Diabetes on Clinical Outcomes after Revascularization with Sirolimus-Eluting and Birolimus-Eluting Stents with Biodegradable Polymer. From the SORT OUT VII Trial

Presenter: Kevin J. Beatt, Frederick Feit

October 31, 2016

Presentation TCT 2016

TCT 52: Proportion and Morphological Features of Restenosis Lesions With Acute Coronary Syndrome in Different Timings of Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation

Presenter: Michael J. Cowley, Franz-Josef Neumann, Shunsuke Kubo

October 31, 2016

News Industry News

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

October 31, 2016

Presentation TCT 2016

TCT 69: A Randomized Comparison of the Second Generation Biodegradable Polymer Sirolimus-Eluting Stent (EXCEL-II) and the First Generation EXCEL-I Stent in Patients With De Novo Coronary Lesions: Clinical and Angiographic Outcomes of the CREDIT II Trial

Presenter: Giuseppe De Luca, Christoph A. Kaiser, Li Zhi

October 31, 2016

Presentation TCT 2016

FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Bo Xu

October 31, 2016

Presentation TCT 2016

TCT 31: Impact of Strut Thickness on Short-term Healing Response After Bioresorbable Scaffold Implantation: Serial OCT Evaluation of Novel Thin Strut Sirolimus-Eluting BRS vs Thick Strut Everolimus-Eluting BRS in Porcine Coronary Arteries

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Pawel Gasior

October 31, 2016

Advertisement

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

PRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients With Coronary Artery Chronic Total Occlusions

NeoVas PLLA-Based Sirolimus-Eluting Scaffold: Early Results and Phase III Completion

FIRESORB PLLA-Based Sirolimus-Eluting Scaffold: 6-Month FUTURE-I Results

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

TCT 261: Impact of Diabetes on Clinical Outcomes after Revascularization with Sirolimus-Eluting and Birolimus-Eluting Stents with Biodegradable Polymer. From the SORT OUT VII Trial

TCT 52: Proportion and Morphological Features of Restenosis Lesions With Acute Coronary Syndrome in Different Timings of Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

TCT 69: A Randomized Comparison of the Second Generation Biodegradable Polymer Sirolimus-Eluting Stent (EXCEL-II) and the First Generation EXCEL-I Stent in Patients With De Novo Coronary Lesions: Clinical and Angiographic Outcomes of the CREDIT II Trial

FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

TCT 31: Impact of Strut Thickness on Short-term Healing Response After Bioresorbable Scaffold Implantation: Serial OCT Evaluation of Novel Thin Strut Sirolimus-Eluting BRS vs Thick Strut Everolimus-Eluting BRS in Porcine Coronary Arteries

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content